RCUS Stock - Arcus Biosciences, Inc.
Unlock GoAI Insights for RCUS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $258.00M | $117.00M | $112.00M | $383.00M | $78.00M |
| Gross Profit | $258.00M | $117.00M | $112.00M | $383.00M | $78.00M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-330,000,000 | $-340,000,000 | $-280,000,000 | $54.00M | $-124,000,000 |
| Net Income | $-283,000,000 | $-307,000,000 | $-267,000,000 | $53.00M | $-123,000,000 |
| Net Margin | -109.7% | -262.4% | -238.4% | 13.8% | -157.7% |
| EPS | $-3.14 | $-4.15 | $-3.71 | $0.76 | $-2.13 |
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
Visit WebsiteEarnings History & Surprises
RCUSEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 24, 2026 | $-0.97 | — | — | — |
Q4 2025 | Oct 28, 2025 | $-1.33 | $-1.27 | +4.5% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $-1.14 | $-0.08 | +93.4% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-1.02 | $-1.14 | -11.8% | ✗ MISS |
Q1 2025 | Feb 25, 2025 | $-1.17 | $-1.03 | +12.0% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-1.07 | $-1.00 | +6.5% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-1.02 | $-1.02 | 0.0% | = MET |
Q2 2024 | May 8, 2024 | $-0.97 | $-0.05 | +94.8% | ✓ BEAT |
Q1 2024 | Feb 21, 2024 | $-1.09 | $-1.08 | +0.9% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-1.12 | $-0.94 | +16.1% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $-1.00 | $-1.04 | -4.0% | ✗ MISS |
Q2 2023 | May 9, 2023 | $-1.06 | $-1.09 | -2.8% | ✗ MISS |
Q1 2023 | Feb 28, 2023 | $-0.99 | $-0.93 | +6.1% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $-1.05 | $-0.90 | +14.3% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $-0.93 | $-0.93 | 0.0% | = MET |
Q2 2022 | May 9, 2022 | $0.83 | $-0.96 | -215.7% | ✗ MISS |
Q1 2022 | Feb 23, 2022 | $-0.74 | $3.71 | +601.4% | ✓ BEAT |
Q4 2021 | Nov 8, 2021 | $-1.13 | $-1.11 | +1.8% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-0.77 | $-1.09 | -41.6% | ✗ MISS |
Latest News
Frequently Asked Questions about RCUS
What is RCUS's current stock price?
What is the analyst price target for RCUS?
What sector is Arcus Biosciences, Inc. in?
What is RCUS's market cap?
Does RCUS pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to RCUS for comparison